MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Psychosis"

  • 2023 International Congress

    Parkinson’s disease-associated psychosis in a Brazilian sample: worse cognitive outcomes, higher LEDD and longer disease duration.

    H. Dourado, C. Lobo, G. Procópio, AE. Lima, MA. Silveira, L. de Almeida, IJ. Oliveira, G. Valença (Salvador, Brazil)

    Objective: To describe the prevalence of Parkinson's Disease (PD) associated psychosis (PDAP) at a Brazilian movement disorders outpatient and to evaluate its associated factors. Background:…
  • 2022 International Congress

    Alteration of lysosomal enzymatic activities in blood of patients with schizophrenia

    A. Bezrukova, K. Basharova, M. Nikolaev, E. Palchikova, I. Miliukhina, G. Baydakova, N. Zalutskaya, E. Zakharova, S. Pchelina, T. Usenko (Gatchina, Russian Federation)

    Objective: To estimate whether alteration of lysosomal activities contributes to schizophrenia (SCZ) pathogenesis, age at onset and risk of developing the disease. Background: SCZ is…
  • 2022 International Congress

    Antipsychotic use in Parkinson’s disease: a single center retrospective chart review

    S. Brooker, C. Yeh, D. Larson (Chicago, USA)

    Objective: To assess the prevalence of antipsychotic (AP) use in people with Parkinson’s disease (PwP), and identify factors associated with AP prescription and differences in…
  • 2022 International Congress

    Longitudinal study of clinical symptoms associated with psychosis in Parkinson’s disease without dementia

    J. Flanigan, M. Harrison, B. Shah, J. Patrie, K. Wyman-Chick, W. Dalrymple, S. Sperling, M. Barrett (Charlottesville, USA)

    Objective: Examine clinical features associated with psychosis among Parkinson’s disease (PD) patients without dementia. Background: Previously identified risk factors for PD psychosis include duration and…
  • 2022 International Congress

    A dose-response study of the effect of the mGlu2/3 orthosteric antagonist LY-341,495 on the anti-dyskinetic and anti-psychotic effect of the mGlu2 positive allosteric modulator LY-487,379 in the MPTP-lesioned marmoset

    S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

    Objective: To assess the effects of different doses of the metabotropic glutamate 2 and 3 (mGlu2/3) orthosteric antagonist (OA) LY-341,495 on the anti-dyskinetic and anti-psychotic…
  • 2022 International Congress

    Evaluation of the effect of adding a mGlu2/3 orthosteric antagonist to a highly selective 5-HT2A antagonist on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset

    S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

    Objective: To determine whether the therapeutic effect of serotonin 2A (5-HT2A) receptor antagonism on dyskinesia and psychosis may be reversed by orthosteric antagonism of metabotropic…
  • 2022 International Congress

    Epidemiologic And Clinical Features Of Psychiatric Disorders In Patients With Parkinson’s Disease – A Retrospective Cohort Study

    O. Koniashvili, G. Khachiashvili, L. Gabunia (Tbilisi, Georgia)

    Objective: We aimed to assess the average duration of Parkinson's disease at the time patient was diagnosed with specific neuropsychiatric disturbance, to study their prevalence…
  • 2022 International Congress

    Non-Invasive Brain Stimulation for the Treatment of Psychiatric Symptoms in Parkinson’s Disease: A Systematic Review and Meta-analysis

    Y. Qu (Wuhan, China)

    Objective: This meta-analysis aims to assess the effect of NIBS technique for psychiatric symptoms in patients with PD. Background: Non-invasive brain stimulations (NIBS), especially repetitive…
  • 2022 International Congress

    ER Visits and Hospitalizations Among Patients Treated with Pimavanserin or Other-AAPs for Parkinson’s Disease Psychosis: Analysis of Medicare beneficiaries

    S. Kumar, N. Rashid, D. Doshi, K. Rajagopalan (Dover, USA)

    Objective: To examine health resource utilization (HRU) outcomes among PDP patients treated with PIMA vs. other AAPs. Background: Real-world analysis demonstrating pimavanserin (PIMA) benefits, the…
  • 2022 International Congress

    Parkinson’s Disease, Cognition, Positive Symptoms and Medication Management

    O. Kaczmarek, S. Baek, A. Sethi, A. Stolarczyk, B. Bumstead, M. Buhse, M. Zarif, B. Anand, M. Gudesblatt (Patchogue, USA)

    Objective: Explore the relationship between multi-domain cognitive testing and patient-reported psychiatric symptoms in PwPD to self-medication management capabilities. Background: Parkinson’s disease (PD) is a complex…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 14
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley